Brian Cheng
Stock Analyst at JP Morgan
(1.36)
# 2,966
Out of 4,479 analysts
52
Total ratings
45.16%
Success rate
-18.53%
Average return
Main Sectors:
Top Industries:
26 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MGX Metagenomi | Downgrades: Neutral | $16 → $6 | $4.23 | +41.84% | 2 | May 2, 2024 | |
| IMNM Immunome | Initiates: Overweight | $24 | $11.70 | +105.13% | 2 | Apr 30, 2024 | |
| PGEN Precigen | Downgrades: Underweight | n/a | $1.49 | - | 2 | Mar 22, 2024 | |
| MRSN Mersana Therapeutics | Upgrades: Neutral | $5 | $1.86 | +168.82% | 3 | Mar 19, 2024 | |
| ITOS iTeos Therapeutics | Maintains: Overweight | $29 → $27 | $14.44 | +86.98% | 1 | Mar 12, 2024 | |
| AHR American Healthcare REIT | Initiates: Outperform | $15 | $15.13 | -0.86% | 1 | Mar 4, 2024 | |
| KYTX Kyverna Therapeutics | Initiates: Overweight | $39 | $8.05 | +384.47% | 1 | Mar 4, 2024 | |
| PTGX Protagonist Therapeutics | Maintains: Overweight | $34 → $37 | $34.59 | +6.97% | 2 | Feb 28, 2024 | |
| ALLO Allogene Therapeutics | Maintains: Overweight | $9 → $8 | $2.16 | +270.37% | 3 | Feb 27, 2024 | |
| EDIT Editas Medicine | Maintains: Neutral | $8 → $9 | $4.54 | +98.24% | 2 | Feb 27, 2024 | |
| IMVT Immunovant | Initiates: Overweight | $51 | $26.52 | +92.31% | 1 | Feb 20, 2024 | |
| CRGX CARGO Therapeutics | Initiates: Overweight | $23 | $15.83 | +45.29% | 1 | Dec 5, 2023 | |
| ROIV Roivant Sciences | Maintains: Overweight | $16 → $15 | $10.56 | +42.05% | 6 | Nov 14, 2023 | |
| APLS Apellis Pharmaceuticals | Maintains: Neutral | $44 → $46 | $34.98 | +31.50% | 4 | Oct 12, 2023 | |
| BCAB BioAtla | Maintains: Overweight | $17 → $14 | $1.32 | +960.61% | 3 | Sep 25, 2023 | |
| ADCT ADC Therapeutics | Upgrades: Neutral | n/a | $3.48 | - | 3 | Aug 10, 2023 | |
| ACET Adicet Bio | Downgrades: Neutral | $20 → $6 | $1.10 | +445.45% | 2 | Jun 1, 2023 | |
| NTLA Intellia Therapeutics | Maintains: Overweight | $82 → $79 | $22.15 | +256.66% | 2 | Mar 31, 2023 | |
| ZYME Zymeworks | Maintains: Neutral | $8 → $9 | $8.40 | +7.14% | 1 | Mar 31, 2023 | |
| XNCR Xencor | Maintains: Overweight | $37 → $42 | $18.26 | +130.01% | 2 | Feb 13, 2023 | |
| SNTI Senti Biosciences | Initiates: Neutral | n/a | $0.39 | - | 1 | Dec 16, 2022 | |
| GOSS Gossamer Bio | Downgrades: Underweight | n/a | $0.96 | - | 2 | Dec 7, 2022 | |
| PSTX Poseida Therapeutics | Initiates: Overweight | $24 | $3.02 | +694.70% | 1 | Jan 7, 2022 | |
| RGLS Regulus Therapeutics | Initiates: Overweight | n/a | $1.76 | - | 1 | Sep 2, 2021 | |
| ARCT Arcturus Therapeutics Holdings | Maintains: Overweight | n/a | $21.48 | - | 2 | Aug 10, 2021 | |
| BCRX BioCryst Pharmaceuticals | Initiates: Overweight | n/a | $6.55 | - | 1 | Aug 3, 2021 |
Metagenomi
May 2, 2024
Downgrades: Neutral
Price Target: $16 → $6
Current: $4.23
Upside: +41.84%
Immunome
Apr 30, 2024
Initiates: Overweight
Price Target: $24
Current: $11.70
Upside: +105.13%
Precigen
Mar 22, 2024
Downgrades: Underweight
Price Target: n/a
Current: $1.49
Upside: -
Mersana Therapeutics
Mar 19, 2024
Upgrades: Neutral
Price Target: $5
Current: $1.86
Upside: +168.82%
iTeos Therapeutics
Mar 12, 2024
Maintains: Overweight
Price Target: $29 → $27
Current: $14.44
Upside: +86.98%
American Healthcare REIT
Mar 4, 2024
Initiates: Outperform
Price Target: $15
Current: $15.13
Upside: -0.86%
Kyverna Therapeutics
Mar 4, 2024
Initiates: Overweight
Price Target: $39
Current: $8.05
Upside: +384.47%
Protagonist Therapeutics
Feb 28, 2024
Maintains: Overweight
Price Target: $34 → $37
Current: $34.59
Upside: +6.97%
Allogene Therapeutics
Feb 27, 2024
Maintains: Overweight
Price Target: $9 → $8
Current: $2.16
Upside: +270.37%
Editas Medicine
Feb 27, 2024
Maintains: Neutral
Price Target: $8 → $9
Current: $4.54
Upside: +98.24%
Immunovant
Feb 20, 2024
Initiates: Overweight
Price Target: $51
Current: $26.52
Upside: +92.31%
CARGO Therapeutics
Dec 5, 2023
Initiates: Overweight
Price Target: $23
Current: $15.83
Upside: +45.29%
Roivant Sciences
Nov 14, 2023
Maintains: Overweight
Price Target: $16 → $15
Current: $10.56
Upside: +42.05%
Apellis Pharmaceuticals
Oct 12, 2023
Maintains: Neutral
Price Target: $44 → $46
Current: $34.98
Upside: +31.50%
BioAtla
Sep 25, 2023
Maintains: Overweight
Price Target: $17 → $14
Current: $1.32
Upside: +960.61%
ADC Therapeutics
Aug 10, 2023
Upgrades: Neutral
Price Target: n/a
Current: $3.48
Upside: -
Adicet Bio
Jun 1, 2023
Downgrades: Neutral
Price Target: $20 → $6
Current: $1.10
Upside: +445.45%
Intellia Therapeutics
Mar 31, 2023
Maintains: Overweight
Price Target: $82 → $79
Current: $22.15
Upside: +256.66%
Zymeworks
Mar 31, 2023
Maintains: Neutral
Price Target: $8 → $9
Current: $8.40
Upside: +7.14%
Xencor
Feb 13, 2023
Maintains: Overweight
Price Target: $37 → $42
Current: $18.26
Upside: +130.01%
Senti Biosciences
Dec 16, 2022
Initiates: Neutral
Price Target: n/a
Current: $0.39
Upside: -
Gossamer Bio
Dec 7, 2022
Downgrades: Underweight
Price Target: n/a
Current: $0.96
Upside: -
Poseida Therapeutics
Jan 7, 2022
Initiates: Overweight
Price Target: $24
Current: $3.02
Upside: +694.70%
Regulus Therapeutics
Sep 2, 2021
Initiates: Overweight
Price Target: n/a
Current: $1.76
Upside: -
Arcturus Therapeutics Holdings
Aug 10, 2021
Maintains: Overweight
Price Target: n/a
Current: $21.48
Upside: -
BioCryst Pharmaceuticals
Aug 3, 2021
Initiates: Overweight
Price Target: n/a
Current: $6.55
Upside: -